NASDAQ:AMYT Amryt Pharma (AMYT) Stock Price, News & Analysis → Trending Stocks Sent To You In Real Time (From Huge Alerts) (Ad) Free AMYT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$14.63▼$14.7650-Day Range$14.55▼$14.7052-Week Range$6.41▼$14.77Volume2.39 million shsAverage Volume757,360 shsMarket Capitalization$940.21 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Amryt Pharma alerts: Email Address Ad DTICBOE shift unlocks new weekend income strategyYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. You're probably wondering, “Okay… But how does that affect me?” This perk now allows everyday traders like yourself to target extra income over the weekend. Check out this training for the full story! About Amryt Pharma Stock (NASDAQ:AMYT)Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.Read More Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. AMYT Stock News HeadlinesOctober 13, 2023 | wsj.comAlembic Pharmaceuticals Ltd.October 10, 2023 | investing.comAMYT Historical DataMarch 28, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… July 28, 2023 | wsj.comBeijing Sun-Novo Pharmaceutical Research Co. Ltd. AApril 11, 2023 | finance.yahoo.com2022 for Chiesi: The Group’s international growth continuesApril 3, 2023 | finance.yahoo.comHigh Court of Justice of England and Wales Sanctions Scheme of ArrangementMarch 17, 2023 | benzinga.comAmryt Pharma Stock (NASDAQ:AMYT), DividendsFebruary 16, 2023 | finance.yahoo.comAMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023March 28, 2024 | DTI (Ad)my top trade on these 9 tickersThis indicator is uniquely designed to spot the most significant moves in the top stocks out there (and according to our backtesting it has historically nailed these moves with a stunning 90% accuracy). Now, most folks have been saying NVDA is way overbought or overpriced. They didn’t want to “buy at the top” 6 weeks ago… Or again 4 weeks ago… or again 2 weeks ago… And it’s not their fault! That’s what all the talking heads were saying too. But the Apex Indicator would have clearly shown that these were opportunities to buy. And, sure enough, Nvidia slammed through the recommended targets again and again.January 9, 2023 | msn.comWhy CinCor Pharma Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving PremarketJanuary 9, 2023 | msn.comEuropean drugmakers including AstraZeneca pony up for U.S.-listed biopharmasJanuary 6, 2023 | markets.businessinsider.comMaxim Group Reaffirms Their Buy Rating on Amryt Pharma (AMYT)January 5, 2023 | finance.yahoo.comAmryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFHNovember 7, 2022 | markets.businessinsider.comSVB Securities Keeps Their Buy Rating on Amryt Pharma (AMYT)November 6, 2022 | seekingalpha.comAmryt Pharma PLC (AMYT) Q3 2022 Earnings Call TranscriptNovember 3, 2022 | finance.yahoo.comAmryt Reports Q3 2022 Financial and Operational ResultsOctober 31, 2022 | msn.comLigand Pharmaceuticals (LGND) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseOctober 27, 2022 | finance.yahoo.comAmryt Pharma PLC Sponsored ADR (AMYT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseOctober 25, 2022 | finance.yahoo.comThe British Journal of Dermatology Publishes Results from Amryt’s EASE Phase 3 Trial in Epidermolysis BullosaOctober 24, 2022 | finance.yahoo.comAmryt Supports Global EB Awareness Week 2022October 19, 2022 | finance.yahoo.comAmryt to Report Q3 2022 Results on November 3, 2022September 23, 2022 | finance.yahoo.comAmryt Supports FH Awareness Day – September 24, 2022September 16, 2022 | marketwatch.comAmryt Pharma Gets CHMP Backing for Mycapssa in Acromegaly >AMYTSeptember 16, 2022 | finance.yahoo.comCHMP adopts positive opinion for Mycapssa® for the treatment of AcromegalySeptember 8, 2022 | msn.comAmryt Secures UK Regulatory Nod And Orphan Disease Status For Skin Disorder CandidateSeptember 8, 2022 | finance.yahoo.comAmryt Receives Marketing Authorisation Approval and Orphan Drug Designation for Filsuvez® in Great BritainSeptember 7, 2022 | finance.yahoo.comAmryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (oral octreotide) at ENEA 2022See More Headlines Receive AMYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amryt Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/05/2020Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AMYT CUSIPN/A CIK1783010 Webwww.amrytpharma.com Phone353-1518-0200FaxN/AEmployees2,020Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$1 million Net Margins-8.19% Pretax Margin-0.56% Return on Equity1.70% Return on Assets0.75% Debt Debt-to-Equity Ratio0.64 Current Ratio1.57 Quick Ratio0.94 Sales & Book Value Annual Sales$222.54 million Price / Sales4.22 Cash Flow$0.98 per share Price / Cash Flow14.98 Book Value$5.58 per share Price / Book2.63Miscellaneous Outstanding Shares63,960,000Free Float60,343,000Market Cap$940.21 million OptionableNot Optionable Beta0.84 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Joseph A. Wiley (Age 51)CEO & Director Comp: $1.65MMr. Rory P. Nealon (Age 54)CFO, COO & Company Sec. Comp: $890kMs. Elizabeth Varki Jobes J.D. (Age 55)Chief Compliance Officer Mr. John McEvoyGen. CounselMr. Stephen JoyceHead of Marketing & Head of APACMs. Julie EastwoodHead of HRDr. Helen PhillipsHead of Medical AffairsMs. Sheila M. Frame (Age 60)Pres of Americas Dr. Tracy CunninghamChief Medical OfficerMr. Jordi CasalsPres of EMEA RegionMore ExecutivesKey CompetitorsABIVAX Société AnonymeNASDAQ:ABVXInnovivaNASDAQ:INVAARS PharmaceuticalsNASDAQ:SPRYORIC PharmaceuticalsNASDAQ:ORICArcutis BiotherapeuticsNASDAQ:ARQTView All Competitors AMYT Stock Analysis - Frequently Asked Questions How were Amryt Pharma's earnings last quarter? Amryt Pharma plc (NASDAQ:AMYT) released its earnings results on Thursday, November, 5th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.66. The business earned $49.33 million during the quarter. Amryt Pharma had a negative net margin of 8.19% and a positive trailing twelve-month return on equity of 1.70%. What other stocks do shareholders of Amryt Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amryt Pharma investors own include Immunic (IMUX), Chimerix (CMRX), Livongo Health (LVGO), Otonomy (OTIC), Akero Therapeutics (AKRO), Albireo Pharma (ALBO), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD) and Applied DNA Sciences (APDN). This page (NASDAQ:AMYT) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amryt Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.